Q2 2024 · 13F-HR
MPM BioImpact LLCholdings as filed
Filed 2024-08-14 · accession 0000950123-24-008626
$643.5M
Reported value
44
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 230031106 | CGEM | Cullinan Therapeutics, Inc. | $133.4M | 20.7% | 7,648,268 | Common | SOLE |
| 457669307 | INSM | Insmed Incorporated | $41.2M | 6.41% | 615,391 | Common | SOLE |
| 68062P106 | OLMA | Olema Pharmaceuticals, Inc. | $28.7M | 4.46% | 2,654,867 | Common | SOLE |
| 46565G104 | 5E7 | iTeos Therapeutics, Inc. | $25.9M | 4.03% | 1,745,943 | Common | SOLE |
| 22663K107 | CRNX | Crinetics Pharmaceuticals Inc. | $25.0M | 3.88% | 557,184 | Common | SOLE |
| 558868105 | MDGL | Madrigal Pharmaceuticals inc | $19.9M | 3.10% | 71,185 | Common | SOLE |
| 462260100 | IOVA | Iovance Biotherapeutics Inc | $19.0M | 2.95% | 2,366,714 | Common | SOLE |
| 632307104 | NTRA | Natera Inc | $18.9M | 2.94% | 174,811 | Common | SOLE |
| 604749101 | MIRM | Mirum Pharmaceuticals Inc | $16.8M | 2.62% | 492,569 | Common | SOLE |
| 90400D108 | RARE | Ultragenyx Pharmaceutical Inc | $15.6M | 2.43% | 380,552 | Common | SOLE |
| 61559X104 | MLTX | Moonlake Immunotherapeutics | $15.1M | 2.35% | 343,235 | Common | SOLE |
| 40131M109 | GH | Guardant Health Inc | $14.4M | 2.24% | 500,000 | Common | SOLE |
| 254604101 | IRON | Disc Medicine Inc | $13.8M | 2.14% | 305,658 | Common | SOLE |
| G01767105 | ALKS | Alkermes Plc | $13.4M | 2.09% | 557,556 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics Inc | $13.3M | 2.07% | 740,661 | Common | SOLE |
| 00166B105 | ALXO | ALX Oncology Holdings Inc. | $13.2M | 2.04% | 2,180,864 | Common | SOLE |
| 61775R105 | MORFUSD | MORPHIC HOLDING INC | $12.6M | 1.96% | 369,384 | Common | SOLE |
| 516544103 | LNTH | Lantheus Holdings Inc | $12.0M | 1.87% | 150,000 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines, Inc. | $11.2M | 1.75% | 289,396 | Common | SOLE |
| 05337M104 | — | Avadel Pharmaceuticals PLC | $11.0M | 1.71% | 783,242 | Common | SOLE |
| 98422E103 | XERS | Xeris Biopharma Holdings Inc | $10.9M | 1.69% | 4,830,526 | Common | SOLE |
| 05464T104 | AXSM | Axsome Therapeutics, Inc. | $10.7M | 1.66% | 132,312 | Common | SOLE |
| 483497103 | KALV | Kalvista Pharmaceuticals Inc | $10.4M | 1.61% | 881,937 | Common | SOLE |
| 45826J105 | NTLA | Intellia Therapeutics, Inc. | $9.9M | 1.54% | 443,503 | Common | SOLE |
| 43157M102 | — | Hillevax Inc | $9.3M | 1.45% | 645,085 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics Inc | $9.1M | 1.41% | 385,990 | Common | SOLE |
| 282559103 | ETNBGBP | 89Bio Inc | $9.0M | 1.40% | 1,121,736 | Common | SOLE |
| 359616109 | FULC | Fulcrum Therapeutics Inc | $9.0M | 1.39% | 1,444,851 | Common | SOLE |
| 869367102 | — | Sutro Biopharma, Inc. | $8.9M | 1.39% | 3,043,346 | Common | SOLE |
| 80706P103 | SRRK | Scholar Rock Holding Corp | $8.6M | 1.33% | 1,028,330 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics Inc. | $8.3M | 1.29% | 1,274,459 | Common | SOLE |
| 816212302 | RNAC | Cartesian Therapeutics Inc | $7.0M | 1.09% | 259,696 | Common | SOLE |
| 75901B107 | RGNX | REGENXBIO Inc. | $6.5M | 1.01% | 557,076 | Common | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $6.3M | 0.98% | 118,960 | Common | SOLE |
| 98943L107 | ZNTL | Zentalis Pharmaceuticals, Inc. | $5.9M | 0.92% | 1,450,000 | Common | SOLE |
| 95075A107 | HOWL | Werewolf Therapeutics, Inc. | $5.8M | 0.91% | 2,388,011 | Common | SOLE |
| 760273102 | RPTX | Repare Therapeutics, Inc. | $5.4M | 0.84% | 1,639,849 | Common | SOLE |
| 05370A108 | RNAGBP | Avidity Biosciences Inc | $5.1M | 0.79% | 125,000 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics, Inc. | $5.0M | 0.78% | 5,005,086 | Common | SOLE |
| 00653A107 | ADAPY | Adaptimmune Therapeutics plc | $5.0M | 0.77% | 5,095,912 | Common | SOLE |
| N44445109 | IMTX | Immatics NV | $4.9M | 0.75% | 417,810 | Common | SOLE |
| 89532M101 | TRVI | Trevi Therapeutics Inc | $4.5M | 0.70% | 1,510,174 | Common | SOLE |
| 92539P101 | — | Verve Therapeutics, Inc | $3.1M | 0.48% | 638,163 | Common | SOLE |
| 01671P100 | ALLKGUSD | Allakos | $344,900 | 0.05% | 344,900 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.